We performed a 5-question survey of 24 oncologists in the US to gauge current prescribing practices for breast cancer treatments, with a focus on HR+/HER2- recurrent or metastatic breast cancer. Drugs and drug candidates discussed:
•Neratinib, PBYI
•Herceptin (trastuzumab), Roche
•Perjeta (pertuzumab), Roche
•Kadcyla (trastuzumab-DM1), Roche
•Tykerb (lapatinib), GSK